Table 2

Truncated prevalence (aged 45–69 years) of upper GI cancer and precursor lesions in the Endoscopic Screening for Esophageal Cancer in China (ESECC) trial in rural Hua County, China, 2012–2016

n=15 188
No. of cases*Truncated prevalence (%)Age-standardised truncated prevalence (China)†Age-standardised truncated prevalence (WHO)‡
Oesophagus
 Normal932361.3862.6462.49
 Acanthosis212714.0013.3513.38
 Oesophagitis227314.9714.2114.37
 Basal cell hyperplasia287518.9318.5918.62
 Squamous dysplasia
   Mild4733.112.792.85
   Moderate870.570.490.49
   Severe630.410.330.35
 Squamous carcinoma in situ160.110.080.08
 Squamous cell carcinoma340.220.180.18
 Total oesophageal high-grade lesions§1130.740.590.61
Gastric cardia
 Severe dysplasia/carcinoma in situ80.050.050.05
 Adenocarcinoma40.030.020.02
 Total120.080.060.07
Gastric non-cardial
 Severe dysplasia40.030.020.02
 Adenocarcinoma/
 Signet-ring cell carcinoma
70.050.030.04
 Total110.070.050.06
Duodenum
 Small cell carcinoma10.010.000.01
 Total10.010.000.01
Total high-grade lesions1370.900.710.74
  • *The total number of cases exceeded 15 188 because multiple pathologic diagnoses could exist in one case for acanthosis, oesophagitis and basal cell hyperplasia.

  • †Truncated prevalence was adjusted by standard population structure of China (The Sixth National Population Census of China, 2010).

  • ‡Truncated prevalence was standardised by the age structure of the world population (WHO, 1985).

  • §Total number of severe squamous dysplasia, squamous carcinoma in situ and squamous cell carcinoma.